Prescription audits document that patients with resistant hypertension are often treated with several vasodilators, with less emphasis on diuretics and beta-blockers. Patients who do not respond to several vasodilators appear to be vasodilator-insensitive; they may be a selected-out cohort who require diuresis or catecholamine suppression for further blood pressure control.

Pulmonary hypertension (PH) is an important cause of heart failure in chronic obstructive pulmonary disease (COPD). The pro brain natriuretic peptide N-terminal (NT-proBNP) has been suggested as a noninvasive marker to evaluate ventricular function. However, there is no evidence to support the use of NT-proBNP in monitoring the benefits of vasodilators in COPD induced PH. Thus, we used NT-proBN...

BACKGROUND Treatment of decompensated heart failure often includes the use of intravenous vasoactive medications, but the effect on outcome has not been clearly defined. METHODS Data from 433 patients enrolled in the ESCAPE trial were analyzed to determine 6-month risks of all-cause mortality and all-cause mortality plus rehospitalization associated with the use of vasodilators, inotropes, an...

Topical vasodilators are widely used in reconstructive microsurgery in order to ameliorate intraoperative vascular spasm (vasospasm) and facilitate microvascular anastomoses. There is, however, a paucity of literature to support or discredit this practice. A survey of current practice in UK Plastic Surgery Departments was therefore undertaken. Email questionnaires were sent to all 281 consultan...

Background Pulmonary arterial hypertension (PAH) associated with connective tissue diseases (CTD) (CTD-PAH) remains a difficult challenge in clinical practice. We aimed to evaluate the effects of targeted vasodilators patients severe CTD-PAH. Methods The data 53 CTD-PAH hospitalized at Department Rheumatology and Immunology, Affiliated Drum Tower Hospital Nanjing University Medical School, were...

Pulmonary hypertension is the most ominous complication of connective tissue diseases and its treatment has been a big challenge to clinicians. Vasodilators including epoprostenol (prostacyclin), bosentan (endothelin-receptor antagonist), and a sildenafil (phosphodiesterase type 5 inhibitor) have recently become available in Japan. These vasodilators may improve exercise tolerance, hemodynamics...

Patients with pulmonary hypertension (PH) are at high risk for complications in the perioperative setting and often receive vasodilators to control elevated pulmonary artery pressure (PAP). Administration of vasodilators via inhalation is an effective strategy for reducing PAP while avoiding systemic side effects, chiefly hypotension. The prototypical inhaled pulmonary-specific vasodilator, nit...